Journal
CURRENT OPINION IN IMMUNOLOGY
Volume 24, Issue 2, Pages 217-224Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2011.12.011
Keywords
-
Categories
Funding
- NIH [R01CA56821, P01CA59350, K12 CA120121-01, T32 CA09149-30]
- Swim Across America
- Cancer Research Institute
- Commonwealth Cancer Research Foundation/MSKCC Experimental Therapeutics Center
- John D. Proctor Foundation
- Margaret A. Cunningham Immune Mechanisms in Cancer Research Fellowship Award
- Melanoma Research Alliance
Ask authors/readers for more resources
Modulation of co-inhibitory and co-stimulatory receptors of the immune system has become a promising new approach for immunotherapy of cancer. With the recent FDA approval of CTLA-4 blockade serving as an important proof of principal, many new targets are now being translated into the clinic. Preclinical research has demonstrated that targeting glucocorticoid-induced tumor necrosis factor (TNF) receptor related gene (GITR), a member of TNF receptor superfamily, by agonist antibodies or natural ligand, can serve as an effective anti-tumor therapy. In this review, we will cover this research and the rationale that has led to initiation of two phase 1 clinical trials targeting GITR as a new immunotherapeutic approach for cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available